Wednesday, May 20, 2026
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO NA Magazine > News > Moderna sues Pfizer/BioNTech over Covid vaccine technology

Moderna sues Pfizer/BioNTech over Covid vaccine technology

in News
Moderna sues Pfizer/BioNTech over Covid vaccine technology
Share on LinkedinShare on WhatsApp

Moderna is suing Pfizer and BioNTech for patent infringement in the development of the first U.S. Covid-19 vaccine approved, the company announced Friday.

The Cambridge, Massachusetts firm claims partners Pfizer and BioNTech, without permission, copied mRNA technology that Moderna had patented between 2010 and 2016, well before Covid-19 emerged late 2019.

“We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the Covid-19 pandemic,” Moderna CEO Stephane Bancel said in the statement.

Moderna had been an innovator in the messenger RNA (mRNA) vaccine technology, which shortens approval processes to months, instead of the years it took to be completed.

The lawsuit was filed in U.S. District Court in Massachusetts and the Regional Court of Dusseldorf in Germany.

The U.S. Food and Drug Administration granted emergency use authorization for the vaccine to both Pfizer/BioNTech and Moderna in consecutive weeks in December 2020.

New York based Pfizer and Mainz, Germany based BioNTech are already facing multiple lawsuits from other companies who say the partnership’s vaccine infringes on their patents.

Moderna has also been sued for patent infringement in the U.S. and has an ongoing dispute with the U.S. National Institutes of Health over rights to mRNA technology.

Tags: BioNTechCOVID vaccineFDAModernaPfizer

Related Posts

American Eagle CEO’s startup hits unicorn status in new funding round
News

American Eagle CEO’s startup hits unicorn status in new funding round

Home Depot maintains full-year forecast and prices despite tariffs
News

Home Depot beats earnings estimates, with sales increasing by 5%

Trump traded over $50 million in stocks in Q1, offloading Tesla and buying Apple and Google
News

Trump traded over $50 million in stocks in Q1, offloading Tesla and buying Apple and Google

International Energy Agency says Iran war has caused historic oil market disruption
News

Oil surges as Trump warns ‘Clock is Ticking’ for Iran

Lululemon stock falls after holiday guidance
News

Frustrated Lululemon Board calls founder ‘misguided’ and ‘outdated’

NextEra Energy and Dominion to merge, forming the world’s largest regulated electric utility company
News

NextEra Energy and Dominion to merge, forming the world’s largest regulated electric utility company

Upcoming Fed meeting likely to feature rate cut
News

Federal Reserve Chair Jerome Powell’s term concludes

Blackstone to acquire Skroutz in $74 million deal
News

Cerebras stock slides after impressive IPO debut

Month-long Boeing strike costs company $5 billion
News

China to buy 200 Boeing jets, order could rise to 750

Analyst: Not cutting rates will be an ’embarrassment’ for Fed
News

Kevin Warsh confirmed as new Fed Chair

No Result
View All Result

Recent Posts

  • President and CEO, Dietrich Kuhlmann, shows CEO NA how Navy Federal Credit Union is leveraging its scale, technology investments and member-first culture to serve those who serve
  • How to oil-proof your life
  • Building Executive Presence in Today’s Workplace
  • American Eagle CEO’s startup hits unicorn status in new funding round
  • Home Depot beats earnings estimates, with sales increasing by 5%

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.